Free Trial

This company has been marked as potentially delisted and may not be actively trading.

TenX Keane Acquisition (TENK) Competitors

TENK vs. IKT, FTLF, ALTS, FATE, NMRA, IMRX, NKTX, RAPT, GLSI, and ACTU

Should you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Inhibikase Therapeutics (IKT), FitLife Brands (FTLF), ALT5 Sigma (ALTS), Fate Therapeutics (FATE), Neumora Therapeutics (NMRA), Immuneering (IMRX), Nkarta (NKTX), Rapt Therapeutics (RAPT), Greenwich LifeSciences (GLSI), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.

TenX Keane Acquisition vs. Its Competitors

TenX Keane Acquisition (NASDAQ:TENK) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Inhibikase Therapeutics has a consensus target price of $6.50, indicating a potential upside of 225.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than TenX Keane Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TenX Keane Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Inhibikase Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

70.5% of TenX Keane Acquisition shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 22.9% of TenX Keane Acquisition shares are owned by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.37 beat TenX Keane Acquisition's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
TenX Keane Acquisition Neutral
Inhibikase Therapeutics Neutral

TenX Keane Acquisition's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TenX Keane AcquisitionN/A N/A N/A
Inhibikase Therapeutics N/A -350.63%-201.82%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TenX Keane AcquisitionN/AN/AN/AN/AN/A
Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.75

Summary

TenX Keane Acquisition and Inhibikase Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

Get TenX Keane Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TENK vs. The Competition

MetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ Exchange
Market Cap$21.62M$178.65M$2.01B$9.04B
Dividend YieldN/A5.38%13.71%4.04%
P/E RatioN/A2.4812.2520.14
Price / SalesN/A412.692,671,753.3398.20
Price / CashN/A74.7861.1358.41
Price / BookN/A6.153.265.60
Net IncomeN/A$3.67M-$462.58M$248.43M

TenX Keane Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TENK
TenX Keane Acquisition
N/A$3.25
-25.1%
N/A-61.8%$21.62MN/A0.00N/AHigh Trading Volume
IKT
Inhibikase Therapeutics
1.3092 of 5 stars
$1.85
-5.1%
$6.50
+251.4%
+52.7%$137.53M$260K-0.696
FTLF
FitLife Brands
4.0598 of 5 stars
$13.61
-3.7%
$20.50
+50.6%
-18.1%$132.79M$64.47M16.2020News Coverage
ALTS
ALT5 Sigma
0.0683 of 5 stars
$7.88
+4.1%
N/AN/A$132.04M$12.53M0.00170
FATE
Fate Therapeutics
4.288 of 5 stars
$1.12
-1.8%
$3.83
+242.3%
-62.8%$130.65M$13.63M-0.75550
NMRA
Neumora Therapeutics
2.2027 of 5 stars
$0.78
-1.8%
$9.29
+1,087.1%
-90.1%$128.80MN/A-0.49108News Coverage
IMRX
Immuneering
4.0568 of 5 stars
$3.59
+4.4%
$13.25
+269.1%
+223.1%$123.79M$320K-1.8360Positive News
NKTX
Nkarta
2.3959 of 5 stars
$1.74
+1.8%
$14.33
+723.8%
-67.2%$121.34MN/A-1.15140News Coverage
RAPT
Rapt Therapeutics
4.4177 of 5 stars
$8.01
+9.3%
$24.00
+199.6%
-67.9%$121.21M$1.53M-0.4280Analyst Forecast
GLSI
Greenwich LifeSciences
1.5482 of 5 stars
$9.88
+9.2%
$39.00
+294.7%
-28.9%$120.98MN/A-7.843
ACTU
Actuate Therapeutics
1.9983 of 5 stars
$6.74
+10.0%
$20.50
+204.2%
N/A$120.27MN/A0.0010Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:TENK) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners